Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial

Fertil Steril. 2011 Apr;95(5):1849-52. doi: 10.1016/j.fertnstert.2010.11.040. Epub 2010 Dec 8.


To determine the effects of statins on vascular function, inflammation, and androgen levels in women with polycystic ovary syndrome (PCOS), we randomized 20 women with PCOS who had low-density lipoprotein cholesterol levels >100 mg/dL to atorvastatin (40 mg/day) or placebo for 6 weeks and found that atorvastatin reduced androgen levels, biomarkers of inflammation, and blood pressure; increased insulin levels and brachial artery conductance during reactive hyperemia; and failed to improve brachial artery flow-mediated dilation. We conclude that until additional studies demonstrate a clear risk-to-benefit ratio favoring statin therapy in PCOS, statins should only be used in women with PCOS who meet current indications for statin treatment.

Trial registration: ClinicalTrials.gov NCT00529542.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Androgens / blood*
  • Anticholesteremic Agents / pharmacology
  • Anticholesteremic Agents / therapeutic use
  • Atorvastatin
  • Blood Vessels / drug effects*
  • Blood Vessels / physiology
  • Double-Blind Method
  • Female
  • Heptanoic Acids / pharmacology*
  • Heptanoic Acids / therapeutic use*
  • Humans
  • Inflammation / complications*
  • Inflammation / drug therapy
  • Placebos
  • Polycystic Ovary Syndrome / blood
  • Polycystic Ovary Syndrome / complications
  • Polycystic Ovary Syndrome / drug therapy*
  • Polycystic Ovary Syndrome / physiopathology
  • Pregnancy
  • Pyrroles / pharmacology*
  • Pyrroles / therapeutic use*
  • Young Adult


  • Androgens
  • Anticholesteremic Agents
  • Heptanoic Acids
  • Placebos
  • Pyrroles
  • Atorvastatin

Associated data

  • ClinicalTrials.gov/NCT00529542